^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | c-MET inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review
Published date:
08/13/2023
Excerpt:
In the METex14 cohort, median OS in patients receiving METi was 25.4 months versus 10.7 months in patients who did not (HR [95% CI]: 0.532 [0.340-0.832]; P = .0055). In the MET-amplified only cohort, median OS was 20.6 months in patients treated with METi compared with 7.6 months in those without METi (HR [95% CI]: 0.388 [0.152-0.991]; P = .0479).
DOI:
https://doi.org/10.1016/j.cllc.2023.08.011
Source:
Title:
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
Published date:
11/10/2021
Excerpt:
Forty patients diagnosed with advanced NSCLC were included. FISH and NGS were conducted prior to MET inhibitors treatment.….The partial response (PR) rate was 68.0% (17/25 with MET amplification) vs. 6.7% (1/15 without MET amplification); the median progression-free survival (PFS) was 5.4 months versus 1.0 months (P < 0.001).
DOI:
10.1186/s40164-021-00245-y
Source:
Title:
Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
Published date:
06/24/2021
Excerpt:
...a statistically significant OS (17.0 months versus 20.0 months, P = 0.044) was only observed in the MET amplification cohort....MET TKIs could be a better treatment option for patients with METex14 skipping mutations. Concurrent mutations may deteriorate the PFS of MET TKIs in NSCLC patients with MET amplification or METex14 skipping mutations. PIK3CA mutations may confer primary resistance to MET TKIs in patients with MET amplification.
DOI:
https://doi.org/10.3389/fonc.2021.649766
Source:
Title:
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Published date:
11/17/2020
Excerpt:
Common treatments (METex14 vs METamp) were platinum-based therapy (1st line [1L], 44 vs 41%; 2nd line [2L], 35 vs 30%) and MET inhibitor monotherapy (1L, 33 vs 29%; 2L, 30 vs 39%). Immune checkpoint inhibitors (±chemotherapy) were used across 1L (13 vs 16%) and 2L (35 vs 13%). Median (95% CI) overall survival from start of 1L therapy (any) was 12.0 months (6.8, 19.2) in METex14 and 22.0 months (9.8, 31.2) in the METamp cohort.
